EHEric Hesse

Eric Hesse

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eric Hesse has a total of 89 co-authors. Here are the top co-authors by number of shared publications:

  • Hanna Taipaleenmäki

    Institute of Musculoskeletal Medicine, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München , 82152 Planegg-Martinsried

    5 shared publications
  • Hanna Taipaleenmäki

    Institut für Muskuloskelettale Medizin, LMU Klinikum, LMU München, München, Deutschland

    3 shared publications
  • Carl Haasper

    Orthopaedic Surgery Bremerhaven, Bremerhaven, Germany

    2 shared publications
  • Hiroaki Saito

    Molecular Skeletal Biology Laboratory, Department of Orthopedics and Trauma Surgery, University Medical Center Hamburg-Eppendorf , D-20251 Hamburg

    2 shared publications
  • Miki Maeda

    Molecular Skeletal Biology Laboratory, Department of Orthopedics and Trauma Surgery, University Medical Center Hamburg-Eppendorf , D-20251 Hamburg

    2 shared publications
  • Ulla Stumpf

    Klinik für Orthopädie und Unfallchirurgie, LMU Klinikum, LMU München, München, Deutschland

    2 shared publications

Latest Publications

  • Open Access

    Bone-derived Osterix+ osteolineage cells are a source of tumor-promoting myofibroblastic cancer-associated fibroblasts in breast cancer

    by Giulia Furesi, Carisa Zeng, Emily M. Eul, Jennifer Zarrer, Deborah J. Veis, Jiayu Ye, Vasilios A. Morikis, Taylor Malachowski, Darya Khantakova, Alina Ulezko Antonova, et al.

    Cancer-associated fibroblasts (CAFs) are major regulators of breast cancer (BC) progression and therapeutic resistance, yet the extent to which CAF heterogeneity is dictated by distinct cellular origins remains unresolved. Here, we identify bone-derived Osterix + (Osx) osteolineage cells as a source of CAFs in BC. Using BC models in female mice and biopsies from women with BC, we show that bone-resident Osx + cells are recruited to primary tumors. These cells preferentially differentiate into a myofibroblastic CAF subset with unique osteolineage identity (OsteoLin-myCAFs). OsteoLin-myCAFs are transcriptionally and functionally distinct from other subsets, exhibit enhanced extracellular matrix remodeling and pronounced pro-tumorigenic activity. Mechanistically, Osx drives expression of matrix-remodeling programs, including MMP13, which supports tumor growth. Cross-species analyses show a conserved 54-gene osteolineage signature in myCAFs from human BC samples, strongly associated with poor survival. Together, these findings identify a distinct bone-derived osteolineage cell that gives rise to OsteoLin-myCAFs and is linked to adverse clinical outcomes.


  • Tgif1-deficiency impairs osteoclast differentiation through PP2A-mediated ERK1/2 dephosphorylation and attenuates bone loss in mice

    by Miki Maeda, Hiroaki Saito, Amy B P Ribet, Eric Hesse, Hanna Taipaleenmäki

    Bone remodeling is a dynamic process regulated by the activities of osteoclasts and osteoblasts. Imbalances in this process can lead to osteoporosis, a condition characterized by low bone mass and increased fracture risk. The homeodomain protein TG-interacting factor 1 (Tgif1) has been previously identified as a key regulator of osteoblast function. Here, we investigate the cell-autonomous role of Tgif1 in osteoclasts. Our findings reveal that Tgif1 is expressed in osteoclast precursors, with its expression increasing during RANKL and M-CSF-induced differentiation. Deletion of Tgif1 in the osteoclast lineage impairs osteoclast differentiation and resorption capacity, reducing aging-related bone loss in mice in vivo. Mechanistically, Tgif1 restricts ERK1/2 dephosphorylation by suppressing protein phosphatase 2A (PP2A), an ERK1/2 phosphatase. Inhibition of PP2A restores impaired differentiation of Tgif1-deficient osteoclasts, confirming its involvement in this process. These findings establish Tgif1 as an important regulator of osteoclast differentiation, function, and bone resorption, offering new insights into molecular mechanisms controlling bone mass maintenance.


  • Beeinflussung der Frakturheilung durch spezifische Osteoporosemedikamente

    by Ulla Stumpf, Ralf Schmidmaier, Hanna Taipaleenmäki, Wolfgang Böcker, Andreas Kurth, Eric Hesse

    Zusammenfassung Hintergrund Die Volkskrankheit Osteoporose ist definiert durch eine Abnahme der Knochenmasse und -struktur und einer Erhöhung des Risikos für Fragilitätsfrakturen. Zur Behandlung kommen Medikamente zum Einsatz, die entweder antiresorptiv oder anabol auf den Knochenstoffwechsel wirken und potenziell die Heilung osteoporotischer Frakturen beeinflussen können. Andererseits können u. a. Stoffwechselstörungen, Immunsystemdysfunktionen oder Durchblutungsprobleme die Frakturheilung beeinträchtigen. Der gezielte Einsatz von Osteoporosemedikamenten könnte daher eine Strategie zur Förderung einer gestörten Frakturheilung darstellen. Ziel der Arbeit Diese Arbeit hat das Ziel, eine aktuelle Übersicht über die Wirkung in Deutschland zugelassener Osteoporosemedikamente auf die Frakturheilung zu geben. Im Fokus stehen mögliche Einflüsse dieser Medikamente im Rahmen der Osteoporosebehandlung. Zudem wird die aktuelle Studienlage betrachtet, um aufzuzeigen, inwieweit der gezielte Einsatz dieser Medikamente die Frakturheilung verbessern könnte. Material und Methoden Es wurde eine Literaturrecherche in der PubMed-Datenbank unter Verwendung themenspezifischer Schlüsselbegriffe durchgeführt. Berücksichtigt wurden präklinische Studien, klinische Untersuchungen, Übersichtsarbeiten und Metaanalysen, um den aktuellen wissenschaftlichen Stand mit klinischer Relevanz darzustellen. Ergebnisse Präklinische und klinische Studien deuten darauf hin, dass spezifische Osteoporosemedikamente keinen relevanten negativen Einfluss auf die Heilung von Fragilitätsfrakturen haben. Osteoanabole Substanzen zeigen sogar tendenziell eine positive Wirkung auf die Frakturheilung sowohl bei normalen als auch gestörten Heilungsprozessen. Allerdings ist die Studienlage begrenzt, und bisher wurde für keines der Medikamente eine Zulassung für diesen spezifischen Anwendungsbereich erteilt. Diskussion Osteoporosemedikamente mit antiresorptiver oder osteoanaboler Wirkung werden primär zur Behandlung der Osteoporose, insbesondere nach Fragilitätsfrakturen, eingesetzt, um das Risiko weiterer Frakturen zu senken. Eine klinisch relevante Beeinträchtigung der Frakturheilung durch diese Medikamente besteht nicht. Um eine Zulassung dieser Medikamente zur Verbesserung der Frakturheilung zu ermöglichen, wären weitere Studien notwendig.


  • Open Access

    Paradoxical combination of osteosclerosis and osteopenia in an adult woman with biallelic TNFRSF11A loss-of-function variants escaping nonsense-mediated decay

    by Dario Gajewski, Anna Floriane Hennig, Regina Grün, Heide Siggelkow, Svenja Vishnolia, Leonard Bastian, Hanna Taipaleenmäki, Ansgar Schulz, Uwe Kornak, Eric Hesse

    Osteoclasts are essential for bone resorption, playing a crucial role in skeletal development, homeostasis, and remodeling. Their differentiation depends on the RANK receptor encoded by the TNFRSF11A gene, with defects in this gene linked to osteoclast-poor sclerosing skeletal dysplasias. This report presents a 37-yr-old woman with normal height, valgus deformities that were treated surgically, frequent fractures, scoliosis, mildly elevated BMD, sclerotic diaphyseal bone, and metaphyseal widening. Initially suspected of having dysosteosclerosis, her diagnosis shifted toward Pyle disease due to the valgus deformity and prominent metaphyseal widening and translucency. Genetic analysis identified 2 pathogenic TNFRSF11A variants: a nonsense mutation c.1093G>T, p.(Glu365*) and a frameshift mutation c.1266_1268delinsCC, p.(Leu422Phefs*104). Thus, genetic and clinical assessment converged on the diagnosis of a mild form of dysosteosclerosis. Both mutations introduced premature stop codons but escaped complete nonsense-mediated decay, potentially permitting residual protein function. Analysis of patient-derived osteoclasts cultured on glass surfaces showed partial differentiation. However, in vitro resorptive function was strongly impaired, which was clinically reflected by reduced serum concentration of the bone resorption marker CTx. Despite this impairment, the retained residual resorptive function likely explains the patient’s relatively mild clinical presentation. These findings underscore the complex genetic interactions that affect osteoclast function, leading to a spectrum of phenotypes in osteoclast-related bone disorders.


  • Open Access

    Tgif1-deficiency impairs cytoskeletal architecture in osteoblasts by activating PAK3 signaling

    by Simona Bolamperti, Hiroaki Saito, Sarah Heerdmann, Eric Hesse, Hanna Taipaleenmäki

    Osteoblast adherence to bone surfaces is important for remodeling bone tissue. This study demonstrates that deficiency of TG-interacting factor 1 (Tgif1) in osteoblasts results in altered cell morphology, reduced adherence to collagen type I-coated surfaces, and impaired migration capacity. Tgif1 is essential for osteoblasts to adapt a regular cell morphology and to efficiently adhere and migrate on collagen type I-rich matrices in vitro. Furthermore, Tgif1 acts as a transcriptional repressor of p21-activated kinase 3 (Pak3), an important regulator of focal adhesion formation and osteoblast spreading. Absence of Tgif1 leads to increased Pak3 expression, which impairs osteoblast spreading. Additionally, Tgif1 is implicated in osteoblast recruitment and activation of bone surfaces in the context of bone regeneration and in response to parathyroid hormone 1–34 (PTH 1–34) treatment in vivo in mice. These findings provide important novel insights in the regulation of the cytoskeletal architecture of osteoblasts.


  • Open Access

    Fibrous Dysplasia of the Jaw: Advances in Imaging and Treatment

    by Katharina Theresa Obermeier, Jens Tobias Hartung, Tim Hildebrandt, Ina Dewenter, Wenko Smolka, Eric Hesse, Florian Fegg, Sven Otto, Yoana Malenova, Anusha Abdullah

    A total of 7% of all benign bone lesions are diagnosed as fibrous dysplasia (FD). The symptoms of FD of the jaw range from asymptomatic to dental anomalies, pain and facial asymmetry. Due to its resemblance to other fibro-osseous bone lesions, misdiagnosis often occurs and can lead to inadequate treatment. Particularly in the jaw, this lesion does not become quiescent during puberty, making fundamental knowledge about the diagnosis and treatment of FD crucial. Mutational analysis and nonsurgical approaches offer new diagnostic and therapeutic options. In this review, we examine the advances and the difficulties of the diagnosis and the various treatment modalities of FD of the jaw in order to capture the current scientific knowledge on this bone disease.


  • Spezielle Aspekte bei Frakturen des fragilen Knochens

    by Evi Fleischhacker, Johannes Gleich, Eric Hesse, Benjamin Bücking, Ulrich C. Liener, Carl Neuerburg

  • Open Access

    Regulation of bone homeostasis by MERTK and TYRO3

    by Janik Engelmann, Jennifer Zarrer, Victoria Gensch, Kristoffer Riecken, Nikolaus Berenbrok, The Vinh Luu, Antonia Beitzen-Heineke, Maria Elena Vargas-Delgado, Klaus Pantel, Carsten Bokemeyer, et al.

    The fine equilibrium of bone homeostasis is maintained by bone-forming osteoblasts and bone-resorbing osteoclasts. Here, we show that TAM receptors MERTK and TYRO3 exert reciprocal effects in osteoblast biology: Osteoblast-targeted deletion of MERTK promotes increased bone mass in healthy mice and mice with cancer-induced bone loss, whereas knockout of TYRO3 in osteoblasts shows the opposite phenotype. Functionally, the interaction of MERTK with its ligand PROS1 negatively regulates osteoblast differentiation via inducing the VAV2-RHOA-ROCK axis leading to increased cell contractility and motility while TYRO3 antagonizes this effect. Consequently, pharmacologic MERTK blockade by the small molecule inhibitor R992 increases osteoblast numbers and bone formation in mice. Furthermore, R992 counteracts cancer-induced bone loss, reduces bone metastasis and prolongs survival in preclinical models of multiple myeloma, breast- and lung cancer. In summary, MERTK and TYRO3 represent potent regulators of bone homeostasis with cell-type specific functions and MERTK blockade represents an osteoanabolic therapy with implications in cancer and beyond.


  • Open Access

    Antagonizing microRNA‐19a/b augments PTH anabolic action and restores bone mass in osteoporosis in mice

    by Hanna Taipaleenmäki, Hiroaki Saito, Saskia Schröder, Miki Maeda, Ramona Mettler, Matthias Ring, Ewa Rollmann, Andreas Gasser, Carl Haasper, Thorsten Gehrke, et al.

    Postmenopausal bone loss often leads to osteoporosis and fragility fractures. Bone mass can be increased by the first 34 amino acids of human parathyroid hormone (PTH), parathyroid hormone‐related protein (PTHrP), or by a monoclonal antibody against sclerostin (Scl‐Ab). Here, we show that PTH and Scl‐Ab reduce the expression of microRNA‐19a and microRNA‐19b (miR‐19a/b) in bone. In bones from patients with lower bone mass and from osteoporotic mice, miR‐19a/b expression is elevated, suggesting an inhibitory function in bone remodeling. Indeed, antagonizing miR‐19a/b in vivo increased bone mass without overt cytotoxic effects. We identified TG‐interacting factor 1 (Tgif1) as the target of miR‐19a/b in osteoblasts and essential for the increase in bone mass following miR‐19a/b inhibition. Furthermore, antagonizing miR‐19a/b augments the gain in bone mass by PTH and restores bone loss in mouse models of osteoporosis in a dual mode of action by supporting bone formation and decreasing receptor activator of NF‐κB ligand (RANKL)‐dependent bone resorption. Thus, this study identifies novel mechanisms regulating bone remodeling, which opens opportunities for new therapeutic concepts to treat bone fragility.


  • Update on MicroRNA-based Treatment Strategies

    by Eric Hesse, Franz Jakob, Hanna Taipaleenmäki

    The family of RNAs comprises several members, protein coding mRNAs and a larger group of non- coding RNAs, which include small, approximately 21-25 nucleotides long microRNAs (miRNAs). In addition to an evolving diagnostic use of RNAs, RNAbased drugs are emerging very rapidly in medicine, which is not only-but currently very prominently visible- due to the impressive success of the first- in-class Covid-19 vaccines such as Comirnaty and Moderna (marketed by the companies Biontech/Pfizer and Moderna, respectively). Although administration of RNA-based drugs comes along with several technical obstacles including delivery approaches, the technology is experiencing a breakthrough and technical and conceptual hurdles that may still remain are very likely to be overcome within the near future. It is therefore highly likely that RNAbased pharmacotherapies may revolutionize medicine by improving vaccination concepts but also by providing novel drugs to treat many other conditions like cancer, metabolic- and degenerative diseases and beyond. It is fascinating to witness the rise of such milestones in medicine and is tempting to elaborate which additional accomplishments can be made using this technology towards personalized medicine comprising diagnostic and therapeutic aspects as well as individual drug design. Although the most recent success with mRNA-based and therefore protein coding vaccines currently takes center stage in media and people's life, other types of RNAs that are less prominent to the public, like non-coding miRNAs, also develop very successfully towards diagnostic and therapeutic purposes. While the diagnostic use of miRNAs was reviewed in another article in this issue (see article from Hackl et al., this issue), this brief review will provide an update on the emerging therapeutic implications of miRNAs. Despite the fact that no miRNA-based drug has yet reached clinical approval, several compounds are in preclinical and clinical development for the treatment of various diseases and great progress has been made during the recent years, which also facilitated the establishment of several innovative biotech companies. Several obstacles associated with this novel approach including off-target effects, tissue specificity and delivery systems exist. However, important improvements have already been made and will continue to be made. It can therefore be assumed that treatments using this class of RNA will also further progress and stimulate additional stakeholders to enter the field to develop novel drug candidates as first-in-class medicinal products to address highly unmet clinical needs. This technology is still at its infancy given that miRNAs were uncovered just about 20 years ago but the conditions are promising for the development of next generation miRNA-based drugs.